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is associated with significant, albeit modest, increases in levelsIncrease in plasma esterified F2-isoprostanes following intra-
of F2-isoprostanes esterified in plasma lipoproteins that tendedvenous iron infusion in patients on hemodialysis.
to increase with time. Although it is uncertain whether thisBackground. In epoetin-treated dialysis patients, currently
degree of lipid peroxidation may have deleterious effects, itiron is administered by the intravenous route to maintain opti-
may be sagacious to explore whether this can be prevented bymum erythropoiesis. However, rapid infusion of iron in excess
slow infusion of frequent smaller doses of iron and, if necessary,of transferrin binding capacity can lead to the availability of
along with administration of antioxidants.unbound iron that can theoretically catalyze peroxidation of lipids,
such as low-density lipoprotein (LDL), which when oxidatively
modified is proinflammatory and promotes atherogenesis.
Methods. To address this issue, our study used one of the Iron infused intravenously in large doses may exceed
most specific measures of lipid peroxidation available, namely the binding capacity of transferrin and lead to the avail-
gas chromatography/mass spectometry (GC/MS) analysis of F2- ability of unbound iron in the blood [1, 2]. Unbound ironisoprostanes. Using a prospective design, blood samples were
can catalyze by the Haber-Weiss reaction, thus generatingcollected 15 minutes before (pre) and 30 minutes after (post)
highly reactive hydroxyl radicals that promote lipid per-a one-hour infusion of 700 mg bolus of intravenous iron in 22
adult home-hemodialysis patients on a non-hemodialysis day. oxidation. A prevailing and experimentally supported
Results. With iron-dextran infusion, serum iron markedly mechanism for atherogenesis is based on free radical-
increased (mean SE, 42 4 vs. 311 92 g/dL, P 0.0001) catalyzed oxidation of lipoproteins. Oxidized low-densityand exceeded the transferrin saturation of 100% in 22 out of 22
lipoprotein (LDL) is proinflammatory and has been shownpatients (pre 23  3 vs. post 165  8%, P  0.0001). Plasma
to promote atherogenesis. Macrophages/monocytes scav-concentrations of free F2-isoprostanes did not change signifi-
cantly following infusion of iron (pre 40  5 vs. post 39  6 enge oxidized LDL in the subendothelial space, which
pg/mL). However, levels of F2-isoprostanes esterified in plasma results in foam cell formation that then elaborates pro-
lipoproteins increased significantly in the postinfusion samples inflammatory cytokine and growth factors, and up-regu-(pre 199 19 vs. post 233 25 pg/mL, P 0.004). Pre-infusion
lates adhesion molecules [3, 4]. The leading cause oflevels of serum iron correlated directly with pre-infusion levels
mortality in the dialysis population is cardiovascular dis-of esterified F2-isoprostanes (r  0.56, P  0.008), which per-
sisted in the postinfusion period (r 0.43, P 0.04). However, ease related to coronary atherosclerosis [5]. In theory,
there was no correlation between esterified F2-isoprostanes and repeated intravenous iron infusion can promote LDL per-
serum ferritin levels. In the last four patients in whom blood oxidation and, through the aforementioned mechanism,samples were collected five hours after the intravenous iron
may accelerate atherosclerosis in dialysis population. Po-infusion, there were further increases in esterified F2-isopros-
tentially this may worsen the already elevated mortalitytanes that very closely correlated with postinfusion serum iron
levels (r  0.99, P  0.013). In a control study, the in vitro rate in the dialysis population and undermine the bene-
addition of iron dextran to blood samples did not increase free fits of improved anemia correction from repeated intra-
or esterified F2-isoprostanes, suggesting that the increase in ester- venous iron infusion. The suggestive evidence that in-ified F2-isoprostanes seen in vivo after iron infusion in patients creased intravenous iron administration may increaseis not due to a procedural artifact.
the risk for cardiac events comes from Besarab et al’sConclusion. Collectively our data suggest that high levels of
serum iron appearing soon after a large bolus of iron infusion study in which higher cardiac events and mortality were
observed in the normal hematocrit (Hct) group who,
among other things, also received more intravenous ironKey words: lipid peroxidation, atherogenesis, proinflammation, dial-
ysis, transferrin saturation, redox iron, free iron, anemia, epoetin. [6]. Although the difference in mortality and cardiac
events between the two groups did not reach statisticalReceived for publication April 3, 2001
significance, the study was halted [6].and in revised form May 9, 2001
Accepted for publication May 31, 2001 Recent studies using plasma malondialdehyde (MDA)
measured by the thiobarbituric acid-reacting substances 2001 by the International Society of Nephrology
1525
Salahudeen et al: Iron infusion and esterified isoprostanes1526
(TBA) test and plasma peroxides suggested that intra- had to be clinically stable, established on home hemo-
dialysis for at least six months, and scheduled for intra-venous iron infusion is associated with marked lipid per-
oxidation [2]. However, these methods are nonspecific venous iron administration based on clinical indication.
No change was made in the routine intravenous iron-and are subject to false positive results. Measurements of
peroxides can be used in studies on purified lipids, but infusion protocol for the study except that blood samples
were collected before and after iron infusion. Prior toits use in the biological system is questionable due to
interference from many other oxidized species present the study, the patients’ demographics, medication and
dialysis details, and clinical conditions were assessed.in plasma [7]. Similarly, lipid peroxidation determination
based on the TBA test, which involves heating the testing Also obtained was the dose of total iron infused in each
of the study subjects during the preceding 12 months.material with thiobarbituric acid and measuring the pink
color formed in the process at 532 nm, can provide spuri- The dose of iron dextran administered to our patients
on home-hemodialysis was 700 mg and was ordered byous positive results [7]. The lack of specificity of the TBA
assay when applied to human plasma is amply demon- the patient’s nephrologist based on a “need-based” indi-
cation for iron repletion. The iron-infusion studies in allstrated by the work of Warso and Lands and is discussed
in detail by Halliwell and Gutteridge [8, 9]. Use of iron 22 patients were carried out by the same research nurse
(BO), and the iron dextran preparation used in this studyby an intravenous route has turned out to be a boon for
the management of anemia in dialysis patients as it is was from Schein Pharmaceutical Inc. (Florham Park, NJ,
USA). Iron infusion was carried out on a non-dialysissimple, efficacious, and generally safe. Thus, it is critical
to verify whether there is a true occurrence of lipid per- day to avoid any confounding effect of hemodialysis on
the study. Pre-iron-infusion samples were collected 15 min-oxidation with iron infusion and, if so, whether there is
peroxidation of lipoproteins, an event considered critical utes prior to administration of iron including the test dose.
A 21-gauge plastic catheter was inserted in the patient’sin atherogenesis. We addressed this issue using one of
the most specific measures of lipid peroxidation currently hemodialysis vascular access to draw blood samples. A
needleless system with a Leur-lock adapter was attachedavailable, namely gas chromatography/mass spectometry
to the catheter and flushed with 2 mL 0.9% saline. A(GC/MS) measurement of F2-isoprostanes [10]. These
1 mL waste was drawn prior to all collections to eliminateare formed in vivo by the free radical-induced peroxida-
the possibility of diluting the samples by the saline. Alltion of arachidonic acid, independent of the cyclooxygen-
iron dextran, including the test dose, was administeredase enzyme [11]. Unlike the cyclooxygenase-catalyzed
via a peripheral infusion site in the extremity oppositeprostaglandin production, F2-isoprostanes are initially
the blood-sampling site. All samples were drawn into aformed in situ esterified to tissue lipids and circulating
prechilled syringe and transferred to a prechilled transferlipoproteins, and subsequently are released in free form
tube. A 5 mL tube with potassium ethylenediaminetetra-[12, 13]. A large body of evidence in experimental ani-
acetic acid (EDTA) was used for the F2-isoprostanesmals and humans indicates that measurement of F2-iso-
samples, and a 10 mL SST Gel and clot activator tubeprostanes represent one of the most reliable approaches
was used to collect the other iron-related measurements.to assess lipid peroxidation including LDL peroxidation
Samples for F2-isoprostanes were immediately centri-and oxidant stress in vivo [10, 14, 15].
fuged, and plasma was transferred to a prechilled transferTo test whether intravenous iron infusion is associated
tube and submerged in dry ice until transport to thewith an increase in free and esterified plasma F2-isopros-
84C freezer for storage. All infusions were timed totanes, plasma samples were prospectively collected just
run for one hour. The postinfusion samples were drawnbefore and one half hour after the one-hour infusion
30 minutes after the completion of iron infusion. In last(700 mg) of iron dextran in home hemodialysis patients
four patients, an additional sample was drawn at fiveon a non-hemodialysis day. The results demonstrate that
hours postinfusion (late post) to determine whether therethere was a modest increase in F2-isoprostanes esterified
was a time-related increase in plasma F2-isoprostanes afteron plasma lipoproteins that correlated with serum iron
iron infusion. A control study was also undertaken toconcentration, suggestive of the occurrence of iron-induced
determine whether processing of the sample for F2-iso-lipid peroxidation.
prostanes could lead to ex vivo F2-isoprostane formation.
For this study, iron dextran was added to blood samples
METHODS from healthy volunteers to obtain similar iron levels as
The study protocol, which was approved by the Institu- in patients after iron infusion. Samples were then pro-
tional Review Board of University of Mississippi Medical cessed in the same fashion as the patients’ samples and
Center, was carried out prospectively in 22 patients on were subjected to F2-isoprostane measurements.
home hemodialysis who were managed by the Renal Care Samples were packed in dry ice during shipment to
Group Inc. of Jackson (MS, USA). The selection criteria Vanderbilt University for the F2-isoprostane measure-
ment, and all samples were verified to have arrived in awere that patients should be between 20 to 75 years old,
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Table 1. Serum iron and iron-related parameters in samples takenfrozen state. Laboratory measurements, including serum
15 minutes before and one-half hour after the one-hour infusion
iron, transferrin, and ferritin, were carried out using stan- of 700 mg of iron dextran
dard assay by a dedicated, central clinical laboratory
Iron infusion(RenaLab Inc., Ridgeland, MS, USA) that is part of the
Pre Post P valueRenal Care Group Inc. of USA. Serum iron was mea-
Serum iron lg/dL 4216 31192 0.0001sured by the Ferrozine method, which measures very
Serum ferritin ng/mL 34874 35971 NSlittle of the iron present in iron dextran complexes [16].
TIBC 18346 19149 NS
Plasma concentrations of free and esterified F2-iso- Serum transferrin mg/dL 14437 15139 NS
TSAT % 227 16536 0.0001prostanes were measured by gas chromatography nega-
Data are mean SEM. Abbreviations are: TIBC, total iron-binding capacity;tive ion chemical ionization mass spectrometry as de-
TSAT, transferrin saturation.scribed [17]. The assay has a precision of 6% and an
accuracy of 96%.
Statistical analysis
(42 4 vs. 311 92g/dL, P 0.0001). Serum transferrin
The StatView computer software program from Aba- and ferritin concentrations did not change.
cus Concepts, Inc. (Berkley, CA, USA) was used for
data analysis. The results are reported as mean  SEM. Effect of intravenous iron administration on free and
The comparison between pre-iron and post-iron infusion esterified F2-isoprostanes
groups were carried out by a two-tailed Student t test, Plasma concentrations of free isoprostanes did not
and the correlation was assessed by simple linear regres- change significantly following infusion of iron (pre 40 
sion. P  0.05 was considered statistically significant. 5 vs. post 39 6 pg/mL). However, levels of isoprostanes
esterified in plasma lipoproteins increased significantly
in the postinfusion samples (pre 199  19 vs. post 233 RESULTS
25 pg/mL, P  0.004; Fig. 1A). The levels rose in 16 outPatient characteristics
of 22 patients, fell in four, and were unchanged in two
Twenty-two patients on home hemodialysis were stud-
(Fig. 1B).
ied. These patients were dialyzed three times weekly for
In the last four patients in whom a five-hour postfour hours each session. The mean age was 48 3 years.
infusion sample was collected (late post), the free iso-The mean duration on dialysis was 114  21 months.
prostanes did not increase. The pre-, post-, and late-postTwelve patients were male. Twelve were African Ameri-
values were 33  6, 29  4, and 28  2 pg/mL, respec-cans, and 10 were Caucasians. Diabetes mellitus was re-
tively. However, the mean esterified isoprostanes didcorded as the cause for end-stage renal disease (ESRD)
increase with time insignificantly (N 4), and the respec-in 4, hypertension in 11, and glomerulonephritis in 7,
tive levels were 332 39, 379 60, and 398 46 pg/mL.and 2 patients were cigarette smokers. The mean body
mass index (BMI) was 27.3  1.6. Serum albumin was Relationship between esterified isoprostanes and
4.30  0.07 g/dL. Kt/V was 1.25  0.09, and predialysis serum iron and iron-related parameters
serum creatinine was 12  0.8 mg/dL. All patients used
There was a significantly positive correlation betweenmodified cellulose acetate dialysis membranes. The mean
levels of serum iron and esterified isoprostanes prior toepoetin dose was 4486  826 units, and the Hct was
iron infusion (r  0.56, P  0.008; Fig. 2A). Following34.2  0.8. The mean dose of intravenous iron received
iron infusion, serum iron levels rose rapidly and the rela-by the patients in the preceding 12 months was 1.83 
tionship between iron levels and esterified isoprostanes,0.20 g.
while persistent, became weak soon after iron infusion
Effect of intravenous iron administration on serum (r  0.44, P  0.042; Fig. 2B). In four patients in whom
iron and iron-related parameters plasma-esterified isoprostanes were measured five hours
after the completion of iron infusion, there was a remark-All the patients received 700 mg of iron dextran as a
ably close correlation between the five-hour post infusionone-hour intravenous bolus, and no side effects were
levels of iron and esterified isoprostanes (r  0.99, P reported. The BP did not change significantly with an
0.013; Fig. 2C). Transferrin saturation showed a positiveintravenous iron infusion. The serum iron and iron-related
correlation with the pre-iron infusion levels of esterifiedparameters taken 15 minutes before and 30 minutes after
isoprostanes (r 0.49, P  0.022), but this was lost afterthe one-hour infusion of 700 mg iron dextran are given in
iron infusion as transferrin saturation in 22 out of 22Table 1. With iron dextran infusion, transferrin saturation
exceeded 100% (r 0.10, P 0.68). There was no corre-(serum iron/TIBC  100) exceeded 100% in 22 patients
lation between plasma isoprostanes and serum ferritin(pre 23  3 vs. post 165  8%, P  0.0001), and this
was associated with a significant increase in serum iron levels either before or after iron infusion.
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iron dextran infusion that appear to exceed the binding
capacity of transferrin were not immediately associated
with generalized lipid peroxidation. However, the find-
ings of a modest but significant increase in plasma esteri-
fied F2-isoprotanes after iron infusion and the presence
of a strong correlation between esterified isoprostanes
and serum iron concentrations suggest that iron infusion
may cause low-grade and ongoing peroxidation of lipids
in the plasma, which are contained in lipoproteins.
Iron and other redox metal ions are strong catalysts
for LDL oxidation and, as alluded to earlier, the latter is
widely regarded as a seminal process in the pathogenesis
of atherosclerosis [3, 18–20]. Sullivan hypothesized a link
between body iron and atherosclerosis to explain the gen-
der difference in the incidence of heart disease [21], and
some, but not all, studies support an association between
high levels of iron and the occurrence of heart disease
[22–27]. Employing a more specific measurement of body
iron stores such as the ratio of serum transferrin receptor
to serum ferritin, a recent prospective study showed an
association between increased body iron stores and an
excess risk for myocardial infarction in the general popu-
lation [22, 28]. Data in our study demonstrate a strong
correlation (r  0.56) between the concentrations of
serum iron and plasma-esterified F2-isoprostanes, sug-
gesting that higher plasma iron concentrations lead to
enhanced lipoprotein peroxidation. For these measure-Fig. 1. (A) Levels of esterified F2-isoprostanes in the plasma obtained
ments in our study, technologists blinded for sample de-15 minutes before (pre) and 30 minutes after (post) the one-hour infusion
of 700 mg of iron dextran in 22 patients on a non-hemodialysis day. tails measured the samples and each of these parameters
Data are mean  SEM; *P  0.004 pre-esterified vs. post-esterified was measured in two separate laboratories (F2-isopros-F2-isoprostanes. (B) The pre-iron and post-iron infusion levels of esteri-
tanes at Vanderbilt University and serum iron at Renalfied F2-isoprostanes in individual patients.
Lab, Inc.). Further, samples were carefully collected and
processed to minimize any possibility for ex vivo iron-
induced lipid peroxidation. Our observation that there
Effect of in vitro addition of iron dextran to blood on was strong correlation between plasma iron and F2-iso-
isoprostane levels prostanes in the samples collected prior to iron infusion
points away from the possibility of spurious ex vivo iron-To determine whether the increase in esterified iso-
induced F2-isoprostane formation. Finally, the negativeprostanes in patients after intravenous iron infusion
results of the control experiment involving the additioncould be a procedural artifact, that is, ex vivo autoxida-
of iron dextran to plasma prior to storage and analysistion, iron dextran was added to blood samples from five
of isoprostanes also strongly suggest that the increase inhealthy volunteers (3 males, age 36  5 years, serum
levels of esterified isoprostanes seen in plasma from iron-creatinine 0.9  0.1 mg/dL) such that the serum iron
infused patients is not due to procedural artifact.levels rose from 105 11 to 336 35 g/dL, P 0.0001.
The time-related slow increase in esterified isopros-No differences were seen in the levels of F2-isoprostanes
tanes noted in the last four patients in whom five-hourin plasma to which iron had been added compared to
post infusion samples were collected suggests that lipidlevels in plasma to which no iron had been added. Free
peroxidation following iron infusion is a slow accruingisoprostanes before and after added iron were 71.0 
process. Our study did not show any significant increase9.5 and 71.7  9.5 pg/mL, and the respective values for
in free F2-isoprostanes that often occur with generalizedesterified isoprostanes were 287.8  34.5 and 280.6 
lipid peroxidation, but rather increases were limited to33.5 pg/mL.
F2-isoprostanes esterified in lipids in the plasma compart-
ment. The explanation of why the increased lipid peroxi-
DISCUSSION dation appears not to be generalized but compartmental-
Our study, based on the measurement of free plasma ized to plasma lipids remains to be established, but could
be due to the fact that lipids in the plasma are likelyF2-isoprostane levels, demonstrates that large doses of
Salahudeen et al: Iron infusion and esterified isoprostanes 1529
Fig. 2. (A) Simple regression analysis between serum iron concentra-
tion and plasma-esterified isoprostane levels prior to the infusion of iron.
There was a significant positive correlation (r 0.56, P 0.008) between
pre-infusion levels of serum iron and esterified isoprostanes. (B) Simple
regression analysis between serum iron concentration and plasma-ester-
ified isoprostane levels after the infusion of iron dextran showing a
persistent positive correlation (r  0.43, P  0.04). Iron dextran was
infused in 22 home-hemodialysis patients at 700 mg over one hour on
a non-hemodialysis day, and plasma samples were collected 30 minutes
afterwards. (C) Simple regression analysis between esterified F2-isopros-
tanes measured five hours after iron infusion versus serum iron levels
30 minutes after iron infusion. In the last four patients plasma esterified
isoprostanes were measured five hours after the completion of iron
infusion to determine whether there was a time dependency on iron-
induced esterified F2-isoprostane formation (Results section). There is
a much stronger correlation between the five-hour post infusion of
esterified isoprostanes and serum iron (r 0.99, P 0.013) in this panel
than between 30 minutes of post-infusion esterified F2-isoprostanes and
serum iron displayed in panel B.
exposed to a higher concentration of iron during intrave- Iron administration by the intravenous route is the
most effective and convenient way to administer iron innous infusion than lipids in peripheral tissues.
The marked increase in lipid peroxidation noted in dialysis patients receiving erythropoietin. In recent studies
that employed iron administration by the intravenousone previous study could be due, at least in part, to the
occurrence of spurious lipid peroxidation in vitro [2]. route, there was a significant reduction in the erythropoie-
tin dose while maintaining target hemoglobin levelsWhile employment of high-pressure liquid chromatogra-
phy (HPLC) achieves greater specificity in separating [30, 31]. However, this was associated with an iron admin-
istration-related steady increase in serum ferritin levelsthe TBA-MDA adduct from the reaction mixture, it
must be noted that exposure of carbohydrates and amino [30, 31]. In our own database comprising the Mississippi
cohort of the Renal Care Group, Inc. hemodialysis pa-acids to hydroxyl radicals yields products that give a
genuine TBA-MDA adduct in the TBA assay [9]. Thus, tients, we compared 1450 patients in December of 1996
with 1639 patients in December of 1998 [32]. The use ofTBA assay used in the previous study is not specific for
lipid peroxidation [2]. An additional issue with TBA iron by an intravenous route increased dramatically, as
did the rest of the U.S. dialysis population [33]. Withmethod is that MDA can be formed in vitro during the
assay procedure, and its application to human body fluids this, there was a modest improvement in anemia manage-
ment, but there was also a twofold increase in the numberalso will measure endoperoxides produced enzymically
by the prostaglandin synthesis pathway [9]. Moreover, of patients with serum ferritin over 1000 ng/mL. Cur-
rently, a liberal upper limit is set for iron infusion, thatplatelets are activated and generate thromboxane during
sampling of blood, and the thromboxane synthase gener- is, a TSAT of 50% and a ferritin of 800 ng/mL to facilitate
the correction of functional iron deficiency [34]. A largeates one molecule of MDA for each molecule of throm-
boxane formed [29]. For these considerations, we ad- portion of the iron infused into patients with functional
iron deficiency will not be utilized for red cell formation,dressed this issue using one of the most specific measures
of lipid peroxidation available, namely GC/MS analysis but will be sequestrated into storage iron as demonstrated
by the increase in ferritin levels in the above-mentionedof F2-isoprostanes [10, 14, 15].
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studies. Whether an increase in this form of body iron Roob et al reported the occurrence of lipid peroxidation
even with 100 mg of iron sucrose infusion [2]. In thatmay lead to toxicity is unlikely, because the iron in ferri-
study, however, iron was infused while the patients weretin is in the storage form and is not readily bioavailable.
undergoing hemodialysis. Hemodialysis might in itselfConsistently, ferritin levels did not influence F2-isopros-
provoke oxidative stress through a number of mecha-tane levels in this study. Furthermore, that the high level
nisms [37, 38] and, therefore, it is possible that ongoingof ferritin per se may not directly contribute to iron
hemodialysis procedure might set the stage for a greatertoxicity is supported also by the observation of the lack
oxidative stress even at a lower dose of iron infusion.of undue atherosclerosis in patients and models of hem-
Studies using more specific measures of oxidative stressochromatosis [26, 35]. Unlike ferritin, our study suggests
such as F2-isoprostane measurements by mass spectros-that the high levels of serum iron that often accompany
copy are required to verify whether iron infusion at 100high TSAT might become available for catalyzing lipid
mg per dose is devoid of any potential oxidative effect.peroxidation. Thus, the concern ought to be about the
A significant increase in esterified F2-isoprostanes re-toxicity of high peak concentrations of iron in the blood,
flects the increase in total plasma lipoprotein oxidation,which occurs during and days immediately following the
considered mostly to be of LDL origin, as LDL formintravenous bolus of large quantities of iron [31]. Smaller
the bulk and are susceptible to oxidation [39, 40]. Theredoses of iron administered over the duration of each dial-
were only four patients with diabetes mellitus in thisysis can avoid the high peak and trough levels of iron. This
study, and their pre-iron or post-iron infusion of esterifiedwill avoid potentially overloading the binding capacity of
isoprostanes was not different from the rest of the studytransferrin. If iron was administered at a lower dose (that
subjects. Our patients were routinely prescribed non-is, 12.5 to 25 mg) and more frequently (that is, each
vitamin E-containing multivitamins, but none was ondialysis over 4 hours), the bioavailable iron could be
vitamin E. One patient took over-the-counter multivita-expected to be present persistently without the risk for
mins. Thus, the reason for the modest increase noted inhigh serum iron levels and transferrin supersaturation.
esterified isoprostanes in this study or lack of increase inThus, administering lower doses of iron more frequently,
esterified isoprostanes in four patients with iron infusionat least in theory, is unlikely to lead to plasma lipoprotein
cannot readily be ascribed to variability due the effectperoxidation and tissue iron deposition.
of any significant antioxidant intake. However, studiesAlthough our patients were on home hemodialysis,
are required to test whether antioxidants can attenuateto receive the intravenous iron dextran infusion under
iron-induced increase in plasma F2-isoprostanes.medical supervision, they attended a dialysis center. These
When this study was designed, we predicted that if therepatients were not on dialysis on the day of infusion. The
were to be lipid peroxidation after intravenous blousingclinical routine was that a “total dose” of 700 mg iron
of iron, it would likely be present within an hour or twodextran was to be infused once a month until iron stores
of infusion. The finding that isoprostane levels increaseswere replete. Our finding that iron dextran infusion in
at five hours after infusion suggested that lipid peroxida-large doses can exceed the transferring binding and lead
tion after iron infusion is a slow and accruing phenome-to modest lipid peroxidation suggests that unbound iron
non that might take several hours or possibly days toas theorized could be a catalyst for lipid peroxidation.
peak after iron infusion. Consistent with this notion, theIn childhood iron poisoning, serum iron concentrations
strongest correlation between levels of serum iron andover 250 g/dL can be high enough to exceed the total
esterified isoprostanes was seen in the pre-infusion levels.number of transferrin binding sites in serum [36]. How-
In summary, these data indicate that infusion of highever, it should be noted that certain types of serum assays
doses of iron is associated with very high levels of serumfor iron measure the iron present in iron complexes spu-
iron, saturation of transferrin, and significant, albeit mod-riously. This is particularly true for ferric gluconate rather
est, increase in F2-isoprostanes esterified in plasma lipo-than the iron dextran used in our study, and can lead to
proteins. Although it is uncertain whether this degree oferroneously high results for the oversaturation of trans-
lipoprotein oxidation may have deleterious effects, it mayferrin [16]. The iron assay based on the Ferrozine method
be prudent to explore whether this can be prevented byemployed in our study also is reported to be more specific
modification of the protocol using slow infusion of smallerin that in an in vitro study, the Ferrozine method mea-
and more frequent doses of iron and, if necessary, thatsured only 2.2% (1.2%) of the iron present in iron
the infusion be along with antioxidant administration.dextran when iron dextran was added to serum [16].
It is possible that at a lower dose of 100 mg of iron
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